Kodiak Sciences is a clinical stage biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform (ABC Platform) uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, tarcocimab, is an anti-vascular endothelial growth factor antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, and wet age-related macular degeneration. Co. has utlized its ABC Platform to build a pipeline of product candidates in various stages of development. The KOD average annual return since 2018 is shown above.
The Average Annual Return on the KOD average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KOD average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KOD average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|